Avastin offers patients the chance to live twice as long without their disease advancing
BASEL, Switzerland | November 16, 2007 | Roche announced today that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for Avastin (bevacizumab) for the first-line treatment of patients with renal cell carcinoma (RCC), the most common form of advanced kidney cancer. The CHMP’s decision is based on data from the pivotal phase III AVOREN trial, which showed that adding Avastin to interferon (IFN) gave patients with advanced RCC the chance to live twice as long without their disease progressing (“progression free survival”) compared with interferon alone. It is the first recommendation by a regulatory authority for approval of Avastin for kidney cancer. It follows approvals of Avastin in colorectal (US, EU, Japan), breast (EU) and lung cancer (EU/US).
“The CHMP opinion is encouraging news for European patients suffering from a particularly aggressive and debilitating disease,” commented William M. Burns, CEO of Division Roche Pharma. “It’s another important step in our comprehensive Avastin development program – the biggest ever clinical trial program in oncology. Thanks to its successful and broad use in colon, lung and breast cancer, European doctors and clinics are already familiar with Avastin. We are therefore confident that we can bring Avastin to patients with kidney cancer very quickly once it has been approved by the European authorities.”
“The AVOREN study has shown us that Avastin is an effective and safe treatment for patients with kidney cancer” said Professor Bernard Escudier, Head of Immunotherapy and Innovative Therapy Unit, Institut Gustave-Roussy, Paris, France and Principal Investigator of the pivotal AVOREN study. “This announcement is very significant because this drug offers new therapeutic options in advanced kidney cancer, where chemotherapy and radiotherapy are not as effective as in other cancers.”
On an annual basis, in excess of 200,000 people worldwide will receive a diagnosis of kidney cancer and more than 100,000 people worldwide will lose their lives to the disease1. These figures can be expected to increase as the number of people suffering from cancer in general rises by 50%, as recently estimated by the WHO2.
Avastin Approval Status
Kidney cancer is the fourth cancer type in which Avastin has demonstrated survival benefits. Data from the comprehensive Avastin cancer clinical development programme have resulted in approvals in colorectal, breast, and lung:
— February 2004 (US) and January 2005 (EU) – first-line treatment in patients with metastatic colorectal cancer
— June 2006 (US) – second-line treatment in patients with metastatic colorectal cancer
— October 2006 (US) – first-line treatment in patients with advanced non-small cell lung cancer (NSCLC)
— March 2007 (EU) – first-line treatment in patients with metastatic breast cancer
— April 2007 (Japan) – treatment in patients with advanced or recurrent colorectal cancer
— August 2007 (EU) – first-line treatment in patients with advanced NSCLC
About the AVOREN Study
The AVOREN study is a randomised, controlled, double-blind phase III study that included 649 patients from 101 study sites across 18 countries. In the study patients received treatment with either Avastin and interferon alpha-2a or placebo and interferon alpha-2a, a standard of care in advanced kidney cancer.
The results of the AVOREN trial showed that by adding Avastin to IFN (a current standard of care):
— Progression free survival was almost doubled from a median of 5.4 to 10.2 months
— Tumour response was significantly increased from 12.8% with interferon alone to 31.4% when Avastin was added
— Dose-reduction of IFN did not appear to affect the efficacy of the combination of Avastin (based on PFS event free rates over time, as shown by a sub-group analysis)
The study also showed a trend towards improved overall survival; however, the survival data are still pending. No new or unexpected adverse events were observed.
An interim analysis of AVOREN was performed in December 2006 and the benefits provided by Avastin were so positive that the Drug Safety Monitoring Board (DSMB) recommended that the trial was unblinded and all patients were offered treatment with Avastin. The study demonstrated, for the first time that Avastin also benefits patients in combination with an immunotherapeutic, the class of drugs to which IFN belongs.
About Kidney Cancer
Kidney cancer is more common in men than women (approximately 62% of patients with RCC are male) and incidence increases with age1.
As the most common type of kidney cancer, RCC accounts for nine out of ten cases of the disease. Within this cancer type, there are several sub-types of cancer based on looking at the cells under a microscope. Clear cell renal cell cancer is the most common type. If RCC is diagnosed at an early stage when the cancer is still confined to the kidney, the 5 year survival rates are relatively good at 60 to 75%. However, if diagnosis is made at a later stage and the cancer has already spread to distant sites the 5 year survival rate is less than 5%3. Unfortunately, because kidney cancer is often asymptomatic, the majority of patients are diagnosed at later disease stages.
Treatment options for patients with kidney cancer are limited. Surgical removal of part or the entire kidney forms the mainstay of treatment but is only really successful in early stage disease. In later stage disease, treatment is more often employed with a view of controlling the cancer and improving associated symptoms.
About Avastin
Avastin is the first treatment that inhibits angiogenesis – the growth of a network of blood vessels that supply nutrients and oxygen to cancerous tissues. Avastin targets a naturally occurring protein called vascular endothelial growth factor (VEGF), a key mediator of angiogenesis, thus choking off the blood supply that is essential for the growth of the tumour and its spread throughout the body (metastasis).
Avastin has now demonstrated a progression-free and/or overall survival benefit for patients in four cancer types, namely: colorectal, breast, lung, and renal cell cancer.
Roche and Genentech are pursuing a comprehensive clinical programme investigating the use of Avastin in various tumour types (including colorectal, breast, lung, pancreatic cancer, ovarian cancer, renal cell carcinoma, and others) and different settings (advanced and adjuvant i.e. post-operation). The total development programme is expected to include over 40,000 patients worldwide.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolic disorders and diseases of the central nervous system. In 2006, sales by the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invests approximately 7 billion Swiss francs a year in R&D. Worldwide, the Group employs about 75,000 people. Additional information is available on the Internet at www.roche.com.
All trademarks used or mentioned in this release are protected by law.
1) Parkin DM, Bray F, Ferlay J and Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55; 74 – 108.
2) WHO Information sheet on cancer http://www.who.int/dietphysicalactivity/ publications/facts/cancer/en/ (accessed 24 May 2007)
3) Medline Plus http://www.nlm.nih.gov/medlineplus/ency/article/000516.htm# Causes,%20incidence,%20and%20risk%20factors (accessed 15 August 2007)
SOURCE: ROCHE
